ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Workshop Summary “Incomplete,” Kopans Writes In Letter

April 16, 1993

In Brief: Shingleton Probably Replacement For Marks On Panel; Connie Henke Heads Oncology Nurses

June 8, 1979

Oncology Practice Group Leaves Allegheny For Former Rival UPCI; Will NSABP Follow?

June 30, 2000

Frederick RFP Available Oct. 22; Three Four May Challenge L-B

August 27, 1976

Study Shows MammaPrint Test Can Predict 25-Year Risk Levels

February 28, 2014

CCOP Applications Total 110(At Least), Plus 25 from Research Bases; All 57 Survivors Try Again

November 21, 1986